Natco Pharma is investing $14 million in US biotech firm eGenesis, with the company’s total investment in the project reaching $22 million, according to reports. eGenesis develops genome-engineered organs intended to address shortages of transplantable organs and to expand treatment options for patients with organ failure.
Business outlets describe the funding as being made through convertible promissory notes. The reported allocation is $9.5 million from Natco Pharma (Canada) Inc and $4.5 million from Natco Pharma South Africa, collectively matching the $14 million figure. Other coverage frames the investment in the context of eGenesis’s organ-engineering approach and its potential medical applications, rather than focusing on specific deal mechanics.
Across the sources, the common point is the size of Natco Pharma’s stated investment and the involvement of eGenesis in developing genome-engineered organs, with differing emphasis on overall investment totals versus the breakdown of where the money comes from.
